1. Pink Sheet
  2. >>Pathways & Standards
  3. >>User Fees

House User Fee Mark-Up: Few Tweaks, But Concerns About ALS And Accelerated Approval

 
• By Derrick Gingery

Clinical trial diversity, FDA hiring authority, and inactive ingredient disclosure provisions all get slight modifications. The bill glides through committee, but not without some complaints about agency performance.

Anna Eshoo speaks during Energy and Commerce Committee mark-up
Rep. Anna Eshoo discussed the FDA user fee reauthorization and other bills during a House Energy and Commerce Committee mark-up. • Source: Screenshot

Despite concerns from the brand industry, no major changes were made to provisions in the US Food and Drug Administration’s user fee reauthorization bill allowing generic drug sponsors more inactive ingredient information as it breezed to the House floor.

The bill would require the FDA to tell generic drug sponsors whether their products are qualitatively and quantitatively the same...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from User Fees

Will US FDA’s Missed Hiring Goals Impact Upcoming User Fee Negotiations?

 
• By Derrick Gingery

The FDA only added 39% of the promised new user fee-related hires in FY 2025 and also missed hiring goals for the previous two fiscal years.

US FDA Drug, Biologics Centers Lost Nearly 1,000 Employees In FY 2025 Fourth Quarter

 
• By Derrick Gingery

The hiring and departure data provide more evidence of the extent of the Trump Administration’s efforts to shrink the FDA workforce through cuts and voluntary departures.

US FDA’s Prescription And Generic Drug User Fee Collections May Miss FY 2025 Targets

 
• By Sue Sutter

Both programs were expected to slightly under-collect fees, similar to FY 2024, but an assessment determined the capacity planning adjustment was accurately forecasting the necessary revenue.

October US FDA User Fee Goals: Few Novel Agents, But Many New Indications As Shutdown Looms

 
• By Bridget Silverman

October is unusually low on user fee goals for novel agents, but more than 20 applications for new indications and formulations will keep FDA staff busy, especially in oncology and ophthalmology.

More from Pathways & Standards

First Cohort Shows Many Routes To US FDA’s Commissioner’s National Priority Voucher

 
• By Sarah Karlin-Smith

Experts raised concerns about the pilot program's larger than expected size and the lack of transparency about the reasons the cohort deserved vouchers over a pool that the FDA said included hundreds of candidates.

US FDA Drug, Biologics Centers Lost Nearly 1,000 Employees In FY 2025 Fourth Quarter

 
• By Derrick Gingery

The hiring and departure data provide more evidence of the extent of the Trump Administration’s efforts to shrink the FDA workforce through cuts and voluntary departures.

EMD Serono IVF Candidate Among First US FDA Priority Voucher Recipients As Part Of MFN Deal

 
• By Cathy Kelly

A combination of two individual IVF treatments, Pergoveris has the potential to be a lower cost option in the US, one of the qualifications the FDA wants in a National Commissioner's Priority Voucher candidate.